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Objectives:	To	assess	the	success	of	electrical	cardioversion	for	
the	treatment	of	new-onset	atrial	fibrillation	in	critically	ill	patients	
and	to	evaluate	the	stability	of	sinus	rhythm	in	responders	during	
the	subsequent	24	hours.
Design:	Retrospective	study.
Setting:	Twelve-bed	cardiosurgical	ICU	at	a	university	hospital.
Patients:	 Seventy-two	 consecutive	 patients	 with	 postoperative	
new-onset	atrial	fibrillation	(<	7	d	of	duration)	treated	by	electrical	
cardioversion.
Interventions:	Electrical	cardioversion	using	synchronized	bipha-
sic	shocks.
Measurements and Main Results:	During	144	 electrical	 cardio-
versions,	 209	 shocks	 were	 delivered	 to	 72	 patients.	 Maximal	
energy	(200	J)	was	used	in	85%	of	shocks.	Electrical	cardiover-
sion	 immediately	 restored	sinus	 rhythm	 in	102	sessions	 (71%).	
Pretreatment	with	amiodarone	did	not	increase	the	success	rates.	
During	the	follow-up,	the	percentages	of	sinus	rhythm	decreased	
from	43%	after	1	hour	to	23%	after	24	hours.	However,	at	ICU	
discharge,	 54	 patients	 (75%)	were	 in	 sinus	 rhythm.	Of	 the	 54	
patients	in	sinus	rhythm,	only	18	(33%)	converted	to	sinus	rhythm	
after	repeated	cardioversions,	whereas	the	remaining	36	(66%)	
did	so	spontaneously	or	with	amiodarone.
Conclusions:	 Biphasic	 electrical	 cardioversion	 in	 cardiosurgi-
cal	 ICU	patients	was	 immediately	 successful	 in	 restoring	 sinus	
rhythm	in	71%	of	sessions.	However,	early	relapse	of	atrial	fibril-
lation	was	common	 in	 the	24-hour	 follow-up.	At	 ICU	discharge,	
the	majority	of	patients	were	in	sinus	rhythm,	but	the	efficacy	of	
repetitive	 electrical	 cardioversion	 in	 restoring	 sinus	 rhythm	was	
disappointing.	(Crit Care Med	2015;	43:2354–2359)
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Synchronized electrical cardioversion (ECV) of atrial fibril-lation (AF) is recommended in patients with hemodynamic instability (1–3). ECV may therefore be favorable for criti-
cally ill patients with new-onset AF, although evidence from ran-
domized trials is lacking. Success rates of up to 90% have been 
documented in outpatients (4), but data about conversion rates 
in critically ill are scarce. Mayr et al (5) reported an immediate 
success of 35% in 37 postoperative critically ill patients with new-
onset supraventricular tachycardia. However, several strategies 
have been implemented into clinical practice since. Higher initial 
delivered energy (6, 7), anterior-posterior electrode positioning 
(8, 9), biphasic waveforms (10), and pretreatment with antiar-
rhythmic drugs (11–13) all improve the success of ECV in out-
patients, but the efficacy of these measures in critically ill patients 
is unclear. In this context, a reappraisal of the efficacy of ECV in 
critically ill patients with new-onset AF is warranted. The aims of 
our study were 1) to assess the immediate success of ECV in a car-
diosurgical ICU population, 2) to document the stability of sinus 
rhythm after successful ECV during the subsequent 24 hours, and 
3) to investigate factors influencing the success.
METHODS
Study Site and Population
This study was performed in the cardiosurgical ICU at the 
University Hospital Zurich, Switzerland. In the year 2013, 
1,181 patients were treated in this 12-bed ICU. Median Simpli-
fied Acute Physiology Score (SAPS) and ICU mortality of all 
admitted patients were 31% and 4.3%, respectively.
Consecutive patients with new-onset AF treated by ECV were 
included from September 1, 2013, to September 1, 2014. Patients 
fulfilling the definition of permanent AF or with other forms of 
supraventricular tachycardia were excluded from the analysis.
Definition of New-Onset AF
AF was defined according to the guidelines of the European 
Society of Cardiology (2). Episodes of AF were detected by the 
nurse or physician on the continuous electrocardiogram mon-
itoring and confirmed by a 12-lead electrocardiogram. New-
onset AF was defined as AF for less than 7 days.
ECV
ECV was performed with a ZOLL M-series external defibril-
lator (ZOLL Medical, Chelmsford, MA) and COVIDIEN 
MediTrace Cadence Multi-Function electrodes (COVIDIEN, 
Dublin, Ireland). All applied shocks were electrocardiogram 
triggered (synchronized) and of biphasic waveform. Antero-
posterior electrode positioning was applied if possible. Phy-
sicians were encouraged to administer a high initial energy 
with escalating doses for subsequent shocks. Repeated shocks 
within 15 minutes were defined as an ECV session.
A conversion into sinus rhythm for at least 30 seconds 
during an ECV session was defined as a successful ECV. The 
stability of sinus rhythm during the following 24 hours was 
investigated, and the presence of sinus rhythm at ICU dis-
charge was documented.
Data Collection and Statistical Analysis
Delivered energy, number of shocks, electrode position, and 
immediate success were documented by the treating physicians. 
The remaining data were collected by reviewing the patient’s 
charts. Pretreatment (6 hr before the ECV) and posttreatment 
(after ECV until ICU discharge) with antiarrhythmic drugs 
were recorded. Hemodynamic instability was defined as nor-
adrenaline requirements greater than or equal to 0.1 μg/kg/
min to keep the mean arterial pressure greater than or equal to 
65 mm Hg or a need for inotropes or signs of heart failure or 
evidence of circulatory shock (serum lactate ≥ 2.2 mmol/L or 
central venous oxygen saturation < 60%). Respiratory failure 
was defined as a need for mechanical ventilation. Renal failure 
was defined as serum creatinine greater than or equal to 200 
μmol/L or a need for renal replacement therapy.
Values are given as median (range) or number (percent-
ages), as appropriate. Groups (successful vs unsuccessful ECV) 
were compared using the Mann-Whitney U test or the Fisher 
TAblE 1. baseline Characteristics of the 
Patients at the Onset of Atrial Fibrillation
Variable n = 72
Type of cardiac surgery, n (%)
 Coronary artery bypass grafting surgery 23 (32)
 Valve surgery 37 (51)
 Aortic surgery 26 (36)
 Other cardiac surgery 19 (26)
Left ventricular ejection fraction (%) 55 (10–75)
Simplified Acute Physiology Score II 
(points)
50 (22–106)
Body temperature (°C) 37.0 (33.9–38.6)
Laboratory values at the onset of atrial fibrillation
 Hematocrit (%) 26 (21–41)
 Leukocyte (103/μL) 13 (4.3–40)
 C-reactive protein (mg/L) 128 (1–441)
 Potassium (mmol/L) 4.9 (3.4–7.2)
 Magnesium (mmol/L) 1.04 (0.71–1.73)
 Calcium, ionized (mmol/L) 1.17 (0.99–1.40)
 Troponin T (μg/L) 0.72 (0.02–18)
 Creatinine (μmol/L) 113 (11–458)
Backup pacing, n (%)
 Ventricular only 16 (22)
 Atrial and ventricular 18 (25)
 None 38 (53)
Values	are	given	as	median	(range)	or	number	(%).	Many	patients	received	
combined	surgical	interventions;	therefore,	the	sum	of	the	procedures	
exceeds	100%.	Twelve	patients	(17%)	received	combined	coronary	artery	
bypass	grafting	and	valve	surgery.
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exact test, as appropriate. ECVs were considered stochastically 
independent as groups were compared. AF relapse over time 
was described with the Kaplan-Meier curve, and differences 
between groups were assessed by the log-rank test. The null 
hypothesis was rejected with a two-sided p value of less than 
0.05. All analyses were performed with the use of IBM SPSS 
Statistics, version 21.0 (IBM, Armonk, NY).
Ethical Considerations
The study protocol was approved by the local ethical commit-
tee (KEK-ZH no. 2014-0389). Due to the nature of the study, 
patient’s informed consent was waived by the ethical committee.
RESUlTS
Population
A total of 72 patients were included (72% men; age, 72 yr 
[36–94 yr]; body mass index, 27 kg/m2 [16–41 kg/m2]). AF 
developed on postoperative day 3 (1–29). Table 1 summarizes 
the baseline characteristics of the patients. All patients received 
appropriate anesthesia before ECV.
Immediate Success of Electrical Conversion
Thirty-seven patients (51%) had one ECV; the remaining had 
up to six ECVs during their ICU stay. Finally, a total of 144 
ECVs were analyzed in the study. During those ECVs, 209 
shocks were delivered with a median of 1 (1–5) shock per ECV. 
Figure 1A illustrates the success of ECV after the first, second, 
and third shocks. Finally, the restoration of sinus rhythm was 
achieved in 102 ECVs (71%).
Seventy-five ECVs (52%) were performed with electrodes 
in the anteroposterior position; the remaining required antero-
lateral electrode placements. Eighty-five percent of shocks were 
performed with a maximal biphasic energy of 200 J (Fig. 1B). 
ECVs were performed after 2.75 hours (0–144 hr) from AF 
onset. A comparison between successful ECV and unsuccess-
ful ECV is displayed in Table 2. Immediate ECV success in 
patients with (n = 56) and without (n = 88) aortic surgery was 
44 (79%) and 58 (66%), respectively (p = 0.13). Hemodynamic 
instability was present during 117 ECVs (81%) and had no 
influence on the ECV success (71% vs 70%; p = 1.0). One 
hundred five ECVs (73%) were performed in patients with 
respiratory failure (invasive ventilation, n = 102; noninvasive 
ventilation, n = 3). IV amiodarone was administered during 
the 6 hours before ECV in 94 of 144 cases (150 mg, n = 41; 
≥ 300 mg, n = 54). Amiodarone pretreatment was present in 
68 successful ECVs (67%) and 26 unsuccessful ECVs (62%), 
and therefore, it did not significantly affect the immediate suc-
cess of ECV (p = 0.36). IV esmolol was administered before 10 
ECVs. No differences in the immediate success was observed 
(p = 1.0). Pretreatment with oral antiarrhythmic drugs was not 
performed in any patient.
Stability of Sinus Rhythm
Figure 2 shows the Kaplan-Meier curve documenting the 
percentage of patients in sinus rhythm during the 24 hours 
following ECV. Table 3 summarizes the success rates of ECV at 
different time points. Pretreatment with amiodarone showed 
no significant influence on the maintenance of sinus rhythm 
during the first 24 hours (log-rank test p = 0.61).
Outcome
The median length of ICU stay was 7 days (1–31 d), and ICU 
mortality of the study population was 15%. At ICU discharge, 
54 patients (75%) were in sinus rhythm, whereas 18 patients 
(25%) were still in AF. Of the 54 patients in sinus rhythm, 11 
(20%) converted spontaneously, 25 (46%) after amiodarone 
posttreatment, and 18 (33%) after repeated ECV.
DISCUSSION
We performed a retrospective analysis of 209 shocks delivered 
during 144 ECV to 72 patients with postoperative new-onset 
AF hospitalized in a cardiosurgical ICU. There were three main 
Figure 1. A, Success of electrical cardioversion. The first bars illustrate the 
total numbers of shocks. Shocks not converting atrial fibrillation to sinus 
rhythm are shown as unsuccessful (light gray bars), and those achieving 
conversion to sinus rhythm are classified as successful (hatched bars). 
Black bars illustrate the total number of conversions to sinus rhythm after 
the first, second, and third shock. The success rates were 56%, 65%, and 
69% after the first, second, and third shock, respectively. After four or more 
shocks, the cumulative success rate of electrical cardioversion was 71%. 
b, Delivered energy. The figure illustrates the delivered energies during the 
first, second, and third shock. The first shock was successful in 62% if the 
initial energy was 200 J. With lower energies, the success rate of the first 
shock decreased (36% for 150 J, 22% of 120 J, and 0% for 100 J).
Copyright © 2015 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
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findings: first, the immediate success rate of ECV was 71%; sec-
ond, the stability of sinus rhythm during the subsequent 24 
hours was poor (43% at 1 hr; 23% at 24 hr); third, no factor 
could be identified that differed significantly between success-
ful ECV and unsuccessful ECV. However, repeated electrical 
and/or pharmacologic interventions as well as spontaneous 
TAblE 2. Characteristics of Successful and Unsuccessful Electrical Cardioversion
Variable Total (n = 144) Successful ECV (n = 102) Unsuccessful ECV (n = 42) p
Demographics
 Age (yr) 71 (36–94) 72 (36–91) 70 (47–94) 0.47
 Male gender, n (%) 106 (74) 76 (75) 30 (71) 0.68
 Weight (kg) 75 (46–126) 75 (46–126) 76 (53–126) 0.77
 Body mass index (kg/m2) 27 (16–41) 27 (16–41) 28 (18–41) 0.17
Left ventricular function
 Left ventricular ejection fraction (%) 55 (10–75) 55 (10–73) 55 (20–75) 0.88
Type of cardiac surgery, n (%)
 Coronary artery bypass grafting surgery 46 (32) 29 (28) 17 (41) 0.17
 Valve surgery 76 (53) 51 (50) 25 (60) 0.36
 Aortic surgery 56 (39) 44 (43) 12 (29) 0.13
Simplified Acute Physiology Score II (points) 50 (22–106) 50 (22–106) 47 (24–82) 0.60
Body temperature (°C) 37.2 (33.9–38.8) 37.2 (33.9–38.5) 37.2 (34.7–38.8) 0.91
Hemodynamic status
 Mean arterial pressure (mm Hg) 70 (40–90) 70 (40–90) 63 (40–80) 0.19
 Heart rate (beats/min) 110 (60–200) 110 (60–200) 105 (70–185) 0.17
 Norepinephrine (μg/kg/min) 0.11 (0.00–0.66) 0.10 (0.00–0.66) 0.14 (0.00–0.59) 0.27
 Inotropes 77 (55%) 53 (54%) 24 (60%) 0.57
  Adrenaline 59 (41%) 39 (38%) 20 (48%) 0.35
  Dobutamine 2 (1%) 2 (2%) 0 (0%) 1.0
  Milrinone 42 (29%) 25 (25%) 17 (41%) 0.07
 Svo2/Scvo2 (%) 66 (38–89) 66 (38–89) 67 (50–78) 0.51
 Lactate (mmol/L) 1.2 (0.1–12) 1.2 (0.1–12) 1.3 (0.6–8) 0.23
Organ dysfunction, n (%)
 Respiratory failure 105 (73) 74 (73) 31 (74) 1.0
 Renal failure 50 (35) 37 (36) 13 (31) 0.57
Laboratory values
 Hematocrit (%) 26 (20–41) 26 (20–41) 26 (20–39) 0.47
 Leukocyte (103/μL) 15 (4.3–40) 15 (4.3–40) 16 (5.6–37) 0.21
 C-reactive protein (mg/L) 129 (1–441) 128 (1–422) 138 (1–441) 0.81
 Potassium (mmol/L) 4.9 (3.4–7.2) 4.9 (3.4–7.2) 4.8 (4.1–5.8) 0.31
 Magnesium (mmol/L) 1.06 (0.71–1.73) 1.05 (0.71–1.73) 1.06 (0.82–1.71) 0.16
 Calcium, ionized (mmol/L) 1.16 (0.99–1.44) 1.15 (0.99–1.44) 1.17 (1.02–1.40) 0.43
 Troponin T (μg/L) 0.70 (0.02–18) 0.67 (0.02–18) 0.82 (0.06–7.6) 0.38
Pretreatment with amiodarone 94 (65%) 68 (67%) 26 (62%) 0.70
ECV	=	electrical	cardioversion.
Values	are	given	as	median	(range)	or	number	(%).	p	value	calculated	by	Mann-Whitney	U	test	or	Fisher	exact	test,	as	appropriate.	Svo2/Scvo2	=	mixed/central	
venous	oxygen	saturation	(available	for	120	ECVs).
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conversions led to the fact that 75% of patients with de novo 
AF left the ICU with sinus rhythm.
The immediate success rate of 71% was achieved after one 
or more shocks. After the first shock, a decreasing success-to-
failure ratio was observed during subsequent shocks. Hence, 
the potential small benefit of additional shocks has to be 
weighed against the risk of physical myocardial injury. In clini-
cal practice, the authors suggest maximal two shocks of 200 J 
per ECV and, if necessary, a pause of 2–6 hours before the next 
ECV attempt. The pathophysiologic peculiarities of critically ill 
patients following cardiac surgery, such as inflammation, fluid 
and electrolyte disturbance, adrenergic overstimulation, or 
surgical trauma, are likely to play a central role in the reduced 
success rate of ECV compared with the cardiology outpatient 
setting (14–16).
The success rates of ECV in this study are better compared 
with the percentages described by Mayr et al (5). They analyzed 
the success of ECV in treating new-onset AF in 37 postopera-
tive critically ill patients. Success, defined as conversion and 
persistence of sinus rhythm for at least 5 minutes, was reported 
in 35% of patients. In contrast to the study by Mayr et al (5), 
several recommendations for performing ECV (6–10) were 
implemented in our clinical practice: all delivered shocks were 
of biphasic waveform, 85% used maximal energy (200 J), and 
52% of sessions were performed with anteroposterior elec-
trode position. The different definition of immediate success 
(30 s in our study compared with 5 min in the work of Mayr 
et al [5]) may also partially explain this discrepancy. We chose 
a short time span of 30 seconds to assess the technical success 
of ECV and avoid confusion with early relapses.
We analyzed several factors potentially influencing the suc-
cess of ECV, but none of them showed a statistically significant 
difference between the groups. Even the use of a pretreatment 
strategy with amiodarone did not influence the immediate 
success of ECV. We also tried to find predictors of success in 
multivariable logistic regression, but we did not get any clear 
association (data not shown).
The analysis of the stability of sinus rhythm after success-
ful ECV addressed the clinical relevant aspect of ECV. During 
the 24-hour follow-up, AF relapse frequently occurred: 1 and 
24 hours after ECV, sinus rhythm was present in only 43% 
and 23% of patients, respectively. These results are of con-
cern. The benefit of increased immediate success is lost dur-
ing the first hours because of high relapse rates. A percentage 
of sinus rhythm of 23% after 24 hours is even lower than the 
rate of 31% reported by Mayr et al (5). In light of our data, 
a treatment strategy by ECV alone is likely to be ineffective. 
Therefore, novel strategies for improving the stability of sinus 
rhythm after ECV are urgently needed. Sticherling et al (17) 
showed a decrease in immediate recurrences of AF in patients 
undergoing elective ECV by administrating amiodarone. 
However, amiodarone pretreatment was not associated with a 
higher ECV success in our study.
Spontaneous conversion occurred in 20% of our patients 
with sinus rhythm at ICU discharge. This result is consistent 
with rates of spontaneous conversion in patients admitted for 
new-onset AF (18). In our ICU, amiodarone posttreatment is 
not common practice in patients responding to ECV. Hence, 
posttreatment was only investigated in patients with AF relapse 
and sinus rhythm on discharge. Amiodarone posttreatment led 
to higher percentage of sinus rhythm at ICU discharge than 
repeated ECV (46% vs 33%).
Finally, the SAPS II and the mortality of 15% in the study 
population were higher compared with the yearly averages of 
all patients hospitalized in this particular ICU. We can there-
fore postulate that new-onset AF is associated with increased 
morbidity and mortality and is likely to be a marker of illness 
severity.
limitations of the Study
First, the study was limited to 144 ECVs from 72 patients. 
Nevertheless, this is the largest cohort of surgical ICU patients 
undergoing ECV for AF reported in the literature. The discrep-
ancy between the low number of included patients and the 
high prevalence of AF reported after cardiac surgery may be 
Figure 2. Percentage of sinus rhythm after electrical cardioversion (ECV). 
The figure illustrates the overall frequency of sinus rhythm after ECV. Atrial 
fibrillation persisted after 29% of sessions (unsuccessful ECV), whereas 
ECV was initially successful in restoring sinus rhythm in 71% of sessions.
TAblE 3. Percentage of Patients in Sinus 
Rhythm After Electrical Cardioversion
Time Sinus Rhythm (%)
Immediately after ECV 71
15 min after ECV 51
1 hr after ECV 43
6 hr after ECV 34
12 hr after ECV 30
24 hr after ECV 23
ICU discharge 75
ECV	=	electrical	cardioversion.
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explained by the following factors: first, patients with history 
of permanent AF were excluded from the study; second, only 
AF patients treated with ECV were analyzed, and therefore, 
patients successfully treated with antiarrhythmic drugs or with 
spontaneous conversion were not included in the study; third, 
some patients may have developed postoperative AF after ICU 
discharge. In our opinion, the key messages of our study do 
not substantially depend on the size of the studied population. 
Our data suggest that a larger population might well result in 
statistically significant differences between the risk factors but 
that these differences would most likely be clinically irrelevant.
The studied population is a selected cohort of ICU patients 
because all included patients underwent cardiac and/or major 
vascular surgery. Hence, the results may not be generalized to 
all adult ICU patients.
Detection of episodes or relapses of AF was assessed by real-
time reading of the continuous electrocardiogram monitoring. 
This method reflects usual clinical practice but may miss short, 
subclinical episodes of AF.
The use of anticoagulation for AF was not assessed because 
the majority of included patients (81%) were considered 
hemodynamically unstable, and therefore, the decision to 
perform ECV was not influenced by the coagulation state. In 
addition, the use of anticoagulation in the early postoperative 
period was determined mainly by the surgical bleeding risk.
CONClUSIONS
The management of new-onset AF in critically ill patients is 
challenging and commonly includes ECV. In this retrospective 
study including 144 ECVs in 72 patients, immediate success 
rate of ECV was 71% and therefore higher than previously 
reported in critically ill patients. However, early relapse of AF 
was common, so that only 23% of the patients were still in sinus 
rhythm after 24 hours. Pretreatment with amiodarone did not 
increase the success. At ICU discharge, 75% of patients were 
in sinus rhythm, whereby 20% converted spontaneously, 46% 
after amiodarone posttreatment, and only 33% after repeated 
ECV. Hence, the efficacy of repetitive ECV in restoring sinus 
rhythm was disappointing.
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